Drug Trial Radar · NCT00866619
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
Last checked: Nov 19, 2026Latest source record: Oct 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15,459
Actual
Start
Mar 27, 2009
Primary completion
Mar 1, 2011
Study completion Jan 31, 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- The PATH Malaria Vaccine Initiative (MVI)
- First posted
- Mar 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 weeks, up to 17 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.
Conditions
- Malaria
Interventions
Malaria Vaccine 257049Biological
administered intramuscularly into the left deltoid.
Meningococcal C Conjugate VaccineBiological
administered intramuscularly into the left deltoid.
Cell-culture rabies vaccineBiological
administered intramuscularly into the left deltoid.
TritanrixHepB/HibBiological
administered intramuscularly into the left deltoid.
Polio Sabin Oral Polio Vaccine (GSK)Biological
administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)Time frame: From Month 2.5 to Month 14
- Rate of First or Only Clinical Episode of P. Falciparum Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)Time frame: From Month 2.5 to Month 14
Locations
10 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Ouagadougou, Burkina Faso
GSK Investigational Site
Lambaréné, Gabon
GSK Investigational Site
Kintampo, Ghana
GSK Investigational Site
Kumasi, Ghana
GSK Investigational Site
Kilifi, Kenya
GSK Investigational Site
Kisumu, Kenya
GSK Investigational Site
Lilongwe, Malawi
GSK Investigational Site
Maputo, Mozambique
GSK Investigational Site
Dar es Salaam, Tanzania
GSK Investigational Site
Tanga, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.